--- title: "Why Agilysys Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket" type: "News" locale: "en" url: "https://longbridge.com/en/news/286884679.md" description: "Agilysys Inc (AGYS) shares surged 15.2% to $81.00 in pre-market trading after reporting better-than-expected Q4 results with revenue of $82.95 million and adjusted earnings of 63 cents per share. The company also provided positive FY27 sales guidance. Other notable pre-market movers include Amesite Inc (+235.8%) and Work Medical Technology Group Ltd (-28.7%)." datetime: "2026-05-19T08:47:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286884679.md) - [en](https://longbridge.com/en/news/286884679.md) - [zh-HK](https://longbridge.com/zh-HK/news/286884679.md) --- # Why Agilysys Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket Shares of **Agilysys Inc** (NASDAQ:AGYS) rose in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY27 sales guidance above estimates. Agilysys reported fiscal fourth-quarter revenue of $82.95 million, beating analyst estimates of $81.56 million, according to Benzinga Pro. The hospitality software provider reported fourth-quarter adjusted earnings of 63 cents per share, beating estimates of 50 cents per share. Agilysys shares jumped 15.2% to $81.00 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers - **Amesite Inc** (NASDAQ:AMST) gained 235.8% to $2.64 in pre-market trading following the Detroit-based company's announcement of its largest enterprise deployment to date. - H**aoxi Health Technology Ltd** (NASDAQ:HAO) gained 104.5% to $0.036 in pre-market trading after dipping over 20% on Monday. - **MetaVia Inc** (NASDAQ:MTVA) gained 73% to $1.92 in pre-market trading. - **Onconetix Inc** (NASDAQ:ONCO) rose 24.4% to $0.38 in pre-market trading. On May 13, Onconetix reported first-quarter 2026 operational progress from its fully-owned Swiss subsidiary, Proteomedix AG, developer of Proclarix, a CE-IVD certified blood test designed to identify clinically significant prostate cancer in combination with prostate-specific antigen (PSA) testing. - **SunCar Technology Group Inc** (NASDAQ:SDA) gained 23.4% to $0.86 in pre-market trading after falling 4% on Monday. - **P3 Health Partners Inc** (NASDAQ:PIII) jumped 17.8% to $10.80 in pre-market trading after dipping over 18% on Monday. - **Virax Biolabs Group Ltd** (NASDAQ:VRAX) rose 17.1% to $0.28 in pre-market trading. On May 15, Armistice Capital, LLC, a New York-based hedge fund, filed a Securities and Exchange Commission disclosure revealing a 4.99% beneficial ownership stake of over 1 million ordinary shares. The fund was founded in 2012 by Managing Member Steven Boyd, who signed the filing. - **Hyperliquid Strategies Inc** (NASDAQ:PURR) gained 11% to $7.69 in pre-market trading. - **Bakkt Inc** (NYSE:BKKT) gained 8.4% to $9.45 in pre-market trading after Securities and Exchange Commission filings disclosed insider activity. ### Losers - **Work Medical Technology Grou**p Ltd (NASDAQ:WOK) declined 28.7% to $0.27 in pre-market trading after dipping 42% on Monday. - **Bitcoin Depot In**c (NASDAQ:BTM) tumbled 18.4% to $0.64  in pre-market trading. Bitcoin Depot on Monday announced that it filed for voluntary Chapter 11 protection after tighter regulations and mounting litigation costs pressured operations. - **U-BX Technology Ltd** (NASDAQ:UBXG) fell 18.1% to $0.11 in pre-market trading after the company announced a 1-for-25 reverse stock split that will take effect Friday. - **IP Strategy Holdings In**c (NASDAQ:IPST) fell 18% to $6.06 in pre-market trading after dipping 23% on Monday. - **Wellgistics Health Inc** (NASDAQ:WGRX) fell 18% to $0.14 in pre-market trading after jumping 108% on Monday. - **Hcw Biologics In**c (NASDAQ:HCWB) dipped 17.2% to $1.11 in pre-market trading after gaining 10% on Monday. - A**IM ImmunoTech Inc** (NYSE:AIM) fell 15.9% to $0.34 in pre-market trading. - **Nanobiotix SA – ADR** (NASDAQ:NBTX) shares dipped 7.2% to $45.91 in pre-market trading. - **Sutro Biopharma In**c (NASDAQ:STRO) dipped 7.1% to $32.04 in pre-market trading after falling 12% on Monday. - **Posco Holdings Inc** (NYSE:PKX) fell 6.8% to $73.30 in pre-market trading. _Photo via Shutterstock_ ### Related Stocks - [AGYS.US](https://longbridge.com/en/quote/AGYS.US.md) - [AMST.US](https://longbridge.com/en/quote/AMST.US.md) - [HAO.US](https://longbridge.com/en/quote/HAO.US.md) - [MTVA.US](https://longbridge.com/en/quote/MTVA.US.md) - [ONCO.US](https://longbridge.com/en/quote/ONCO.US.md) - [SDA.US](https://longbridge.com/en/quote/SDA.US.md) - [PIII.US](https://longbridge.com/en/quote/PIII.US.md) - [VRAX.US](https://longbridge.com/en/quote/VRAX.US.md) - [PURR.US](https://longbridge.com/en/quote/PURR.US.md) - [BKKT.US](https://longbridge.com/en/quote/BKKT.US.md) - [WOK.US](https://longbridge.com/en/quote/WOK.US.md) - [BTM.US](https://longbridge.com/en/quote/BTM.US.md) - [UBXG.US](https://longbridge.com/en/quote/UBXG.US.md) - [IPST.US](https://longbridge.com/en/quote/IPST.US.md) - [WGRX.US](https://longbridge.com/en/quote/WGRX.US.md) - [HCWB.US](https://longbridge.com/en/quote/HCWB.US.md) - [AIM.US](https://longbridge.com/en/quote/AIM.US.md) - [NBTX.US](https://longbridge.com/en/quote/NBTX.US.md) - [STRO.US](https://longbridge.com/en/quote/STRO.US.md) - [PKX.US](https://longbridge.com/en/quote/PKX.US.md) - [SDAWW.US](https://longbridge.com/en/quote/SDAWW.US.md) - [PIIIW.US](https://longbridge.com/en/quote/PIIIW.US.md) - [BKKT+.US](https://longbridge.com/en/quote/BKKT+.US.md) - [BTMWW.US](https://longbridge.com/en/quote/BTMWW.US.md) - [AIMID.US](https://longbridge.com/en/quote/AIMID.US.md) - [AIMI.US](https://longbridge.com/en/quote/AIMI.US.md) ## Related News & Research - [Agilysys Announces 17th Consecutive Record Revenue Quarter of $82.9M and Full Year Record Revenue of $319.3M | AGYS Stock News](https://longbridge.com/en/news/286813236.md) - [Why Agilysys Stock Rallied Today](https://longbridge.com/en/news/286975134.md) - [Agilysys Q4 revenue rises on subscription growth](https://longbridge.com/en/news/286814791.md) - [Analyst Reaffirms Buy on Agilysys, Maintains $120 Price Target Amid Strong Growth and Margin Outlook](https://longbridge.com/en/news/286884474.md) - [A Look At Agilysys (AGYS) Valuation As AI-Powered Hospitality Solutions Gain Customer Traction](https://longbridge.com/en/news/286784886.md)